FreeGuest Editorial Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust August 08, 2025Vol.51 No.31By Louis M. Weiner
Book ReviewFree When public service ends abruptly, do books provide solace? An escape? Perspective?Former NIH and FDA employees tell us what they are reading in 2025 August 08, 2025Vol.51 No.31By Sara Willa Ernst
Capitol Hill GOP-led Congress rejects Trump’s plans to gut medical researchSenate bill gives NIH a $400 million raise August 01, 2025Vol.51 No.30By Paul Goldberg
News Analysis Vinay Prasad falls from grace at FDA upon flunking Trump political purity testMAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? August 01, 2025Vol.51 No.30By Claire Marie Porter
U.S. News & World Report expands evaluation of outcomes in cancer subspecialties August 01, 2025Vol.51 No.30By Sara Willa Ernst
Guest Editorial USPSTF doesn’t lean right or left—it’s about data, not politics August 01, 2025Vol.51 No.30By Barnett Kramer
Conversation with The Cancer Letter Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out July 25, 2025Vol.51 No.29By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care? July 25, 2025Vol.51 No.29By Sara Willa Ernst
Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya July 25, 2025Vol.51 No.29By Claire Marie Porter
Sponsored City of Hope brings evidence-based approaches to integrative oncology July 25, 2025Vol.51 No.29By Richard T. Lee
